WO2002085311A3 - Formulation de gonadotropine chorionique humaine - Google Patents

Formulation de gonadotropine chorionique humaine Download PDF

Info

Publication number
WO2002085311A3
WO2002085311A3 PCT/US2002/013269 US0213269W WO02085311A3 WO 2002085311 A3 WO2002085311 A3 WO 2002085311A3 US 0213269 W US0213269 W US 0213269W WO 02085311 A3 WO02085311 A3 WO 02085311A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
relates
hcg
peptide
composition
Prior art date
Application number
PCT/US2002/013269
Other languages
English (en)
Other versions
WO2002085311A2 (fr
Inventor
Hernan F Acevedo
Original Assignee
Hernan F Acevedo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hernan F Acevedo filed Critical Hernan F Acevedo
Priority to EP02764353A priority Critical patent/EP1390053A2/fr
Priority to JP2002582887A priority patent/JP2004529147A/ja
Priority to AU2002338436A priority patent/AU2002338436A1/en
Publication of WO2002085311A2 publication Critical patent/WO2002085311A2/fr
Publication of WO2002085311A3 publication Critical patent/WO2002085311A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/113—Multiple emulsions, e.g. oil-in-water-in-oil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Reproductive Health (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne une composition pharmaceutique comprenant une protéine ou un peptide biologiquement actif formulé dans une émulsion eau dans l'huile avec ou sans peptide de muramyle. L'invention concerne plus spécifiquement une préparation de gonadotropine chorionique humaine (hCG) et des hormones associées. Elle concerne également des procédés de préparation de ladite composition et des méthodes d'utilisation de cette composition contre des infections virales, des troubles immunitaires, et le cancer.
PCT/US2002/013269 2001-04-25 2002-04-25 Formulation de gonadotropine chorionique humaine WO2002085311A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP02764353A EP1390053A2 (fr) 2001-04-25 2002-04-25 Formulation de gonadotropine chorionique humaine
JP2002582887A JP2004529147A (ja) 2001-04-25 2002-04-25 ｈＣＧ処方
AU2002338436A AU2002338436A1 (en) 2001-04-25 2002-04-25 Hcg formulation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28593901P 2001-04-25 2001-04-25
US60/285,939 2001-04-25

Publications (2)

Publication Number Publication Date
WO2002085311A2 WO2002085311A2 (fr) 2002-10-31
WO2002085311A3 true WO2002085311A3 (fr) 2003-08-21

Family

ID=23096335

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/013269 WO2002085311A2 (fr) 2001-04-25 2002-04-25 Formulation de gonadotropine chorionique humaine

Country Status (6)

Country Link
EP (1) EP1390053A2 (fr)
JP (1) JP2004529147A (fr)
CN (1) CN1512890A (fr)
AU (1) AU2002338436A1 (fr)
WO (1) WO2002085311A2 (fr)
ZA (1) ZA200309136B (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7846898B2 (en) 2004-02-13 2010-12-07 Stem Cell Therapeutics Corp. Pheromones and the luteinizing hormone for inducing proliferation of neural stem cells and neurogenesis
US20150038413A1 (en) 2006-02-03 2015-02-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US7553940B2 (en) * 2006-02-03 2009-06-30 Modigene Inc Long-acting EPO polypeptides and derivatives thereof and methods thereof
US8946155B2 (en) 2006-02-03 2015-02-03 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US8048849B2 (en) 2006-02-03 2011-11-01 Modigene, Inc. Long-acting polypeptides and methods of producing same
US10221228B2 (en) 2006-02-03 2019-03-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US20140113860A1 (en) 2006-02-03 2014-04-24 Prolor Biotech Ltd. Long-acting polypeptides and methods of producing and administering same
US9249407B2 (en) 2006-02-03 2016-02-02 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US10351615B2 (en) 2006-02-03 2019-07-16 Opko Biologics Ltd. Methods of treatment with long-acting growth hormone
WO2009149307A2 (fr) * 2008-06-04 2009-12-10 San Diego State University Research Foundation Compositions et procédés pour rétablir la fonction de transfert d’électron mitochondrial
US9663778B2 (en) 2009-07-09 2017-05-30 OPKO Biologies Ltd. Long-acting coagulation factors and methods of producing same
DE102009056871A1 (de) * 2009-12-03 2011-06-22 Novartis AG, 4056 Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben
RU2463066C1 (ru) * 2011-08-19 2012-10-10 Государственное бюджетное образовательное учреждение высшего профессионального образования "Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова" Министерства здравоохранения и социального развития Российской Федерации Фармакологическая антимикробная композиция пролонгированного действия
BR112014025951A2 (pt) 2012-04-19 2017-07-11 Opko Biologics Ltd variantes de oxintomodulina de longa ação e métodos de produção do mesmo
BR112015011583B1 (pt) 2012-11-20 2023-03-14 Opko Biologics Ltd Métodos para aumentar o tamanho ou volume hidrodinâmico de hormônio de crescimento humano, método para aumentar o peso molecular aparente de um polipeptídeo e método para aumentar a meia-vida de um polipeptídeo
US20150065426A1 (en) * 2013-08-27 2015-03-05 Professional Compounding Centers Of America Testosterone Booster Transdermal Compositions
US20150158926A1 (en) 2013-10-21 2015-06-11 Opko Biologics, Ltd. Long-acting polypeptides and methods of producing and administering same
JP2018507227A (ja) 2015-03-03 2018-03-15 キュアポート インコーポレイテッド 二薬搭載リポソーム医薬製剤
US9895313B2 (en) 2015-03-03 2018-02-20 Cureport, Inc. Combination liposomal pharmaceutical formulations
IL301728A (en) 2015-06-19 2023-05-01 Opko Biologics Ltd Long-term coagulation factors and methods for their preparation
CA3030533A1 (fr) 2016-07-11 2018-01-18 Oren HERSHKOVITZ Facteur vii de coagulation a action prolongee et procedes de production associes

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4691006A (en) * 1983-03-04 1987-09-01 Ohio State University Antigenic modification of polypeptides
US5811390A (en) * 1995-08-22 1998-09-22 Metatron, Inc. Use of beta HCG for the control of retroviral infection

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4691006A (en) * 1983-03-04 1987-09-01 Ohio State University Antigenic modification of polypeptides
US5811390A (en) * 1995-08-22 1998-09-22 Metatron, Inc. Use of beta HCG for the control of retroviral infection

Also Published As

Publication number Publication date
WO2002085311A2 (fr) 2002-10-31
JP2004529147A (ja) 2004-09-24
EP1390053A2 (fr) 2004-02-25
ZA200309136B (en) 2005-10-26
AU2002338436A1 (en) 2002-11-05
CN1512890A (zh) 2004-07-14

Similar Documents

Publication Publication Date Title
WO2002085311A3 (fr) Formulation de gonadotropine chorionique humaine
EP2325205A3 (fr) Cristaux d'anticorps complets et de fragments correspondants et leurs procédés de fabrication et d'utilisation
EP1568373A3 (fr) Induction de reponses immunes cellulaires a HER2/neu a l'aide de compositions renfermant des peptides et des acides nucleiques
WO2003002136A3 (fr) Formulation stable de glp-1 modifie
SI1887016T1 (sl) Fragmenti človeškega horijevega gonadotropina (hcg) kot imunoregulator
WO1999010375A3 (fr) Vaccin
GB0100758D0 (en) Immunogenic complex method of preparation thereof and pharmaceutical compositions containing the same, useful for disease control
WO2003030934A3 (fr) Formulations cpg et procedes y relatifs
WO2005007185A3 (fr) Formulation destinee a un agent pharmaceutique proteique ne contenant pas d'albumine serique humaine ajoutee (hsa)
PT1171143E (pt) Extracto peptidico de tremoco e composicao farmaceutica ou cosmetica ou nutraceutica compreendendo o referido extracto
BR0207283A (pt) Anticorpos anti-egfr modificados com imunogenicidade reduzida
WO1998055495A3 (fr) Oligonucleotides immunostimulateurs, compositions correspondantes et leurs procedes d'utilisation
WO2003028757A1 (fr) Nouvelle methode pour induire des lymphocytes t specifiques d'antigenes
WO2002097393A3 (fr) Tensioactifs clivables et procedes d'utilisation associes
NO20054440L (no) Flytende formuleringer av tumornekrosefaktorbindende proteiner
WO2002055098A3 (fr) Methode pour conferer un temps de latence a des substances pharmaceutiquement actives
EP2292255A3 (fr) Proteines thérapeutiques stables
WO2005007673A3 (fr) Peptides immunogenes
RS20050737A (en) Liquid pharmaceutical formulations fish and lh together with a non- ionic surfactant
WO2002044197A3 (fr) Peptides de fixation des recepteurs des cytokines
WO2002005830A3 (fr) Extraits de plantes a photosynthese de type 'cam' et leurs utilisations
EP1801123A3 (fr) Cristaux d'anticorps complets et de fragments correspondants et leurs procédés de fabrication et d'utilisation
WO2001040313A3 (fr) Proteines immunoregulatrices felines, molecules d'acide nucleique et leurs utilisations
EP1364657A4 (fr) Remedes contre les tumeurs affectant les organes hematopoietiques
WO2003093298A3 (fr) Peptides immunogenes

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 02810936.8

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002582887

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002764353

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002764353

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2002764353

Country of ref document: EP